Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand AI‑driven protein design capabilities. The Emeryville company said it will deploy the capital to scale its large‑scale models, commercialize enzyme and therapeutic design offerings, and accelerate partnerships across therapeutics, agriculture and biomanufacturing. Profluent highlighted its Protein Atlas (reported to contain over 115 billion protein entries) and recent collaborations with Integrated DNA Technologies and Revvity as validations of its platform. Management framed the funding as a bridge from computational discovery toward regulatory and manufacturing pathways required for therapeutic applications. The raise follows a broader wave of capital into computational biology and protein‑design startups as investors prioritize platform companies that claim to compress discovery timelines.